Loading...
•
Sep 30, 2023
Marinus Pharmaceuticals Q3 2023 Earnings Report
Marinus Pharmaceuticals reported strong quarter over quarter growth with ZTALMY net product revenue of $5.4 million and increased its 2023 net product revenue guidance.
Key Takeaways
Marinus Pharmaceuticals reported its Q3 2023 financial results, highlighting a ZTALMY net product revenue of $5.4 million. The company increased its full year 2023 expected ZTALMY net product revenues to between $18.5 and $19 million. The company's cash runway is projected into Q4 2024, with cash, cash equivalents, and short-term investments of $176.4 million as of September 30, 2023.
ZTALMY net product revenue reached $5.4 million in Q3 2023.
Full year 2023 ZTALMY net product revenue guidance increased to between $18.5 and $19 million.
Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus.
Cash runway projected into Q4 2024 with $176.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Marinus Pharmaceuticals
Marinus Pharmaceuticals
Marinus Pharmaceuticals Revenue by Segment
Revenue by Segment
Federal Contract Revenue
CapyFin.com Forward Guidance
Marinus Pharmaceuticals updated its revenue and operating expense guidance for the fiscal year 2023.
Positive Outlook
- The Company now expects ZTALMY net product revenues of between $18.5 and $19 million; this represents an increase from the previous guidance of between $17 and $18.5 million